Crossmark

Treatment strategies for ADHD: an evidence-based guide to select optimal treatment

Crossref DOI link: https://doi.org/10.1038/s41380-018-0116-3

Published Online: 2018-06-28

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Caye, Arthur

Swanson, James M.

Coghill, David

Rohde, Luis Augusto
License Information

Text and Data Mining valid from 2018-06-28
More Information

Article History

Received: 23 December 2017

Revised: 20 April 2018

Accepted: 14 May 2018

First Online: 28 June 2018

Compliance with ethical standards

:

: Dr. Caye declares no conflicts of interest. Prof. Coghill reports grants from The European Union FP7 Programme and Shire; honoraria from Shire, Eli-Lilly, Novartis, and Janssen-Cilag; acted as an advisor to Shire and Lundbeck; and received royalties from Oxford University Press. Prof. Coghill was a member of British Association for Psychopharmacology ADHD, Depression and Bipolar Disorder Guideline groups. Prof. Swanson was a member of the advisory board and/or acted as a consultant for Medice and NLS Pharma in 2017. Prof. Rohde has been a member of the speakers’ bureau/advisory board and/or acted as a consultant for Eli-Lilly, Janssen-Cilag, Medice, Novartis, and Shire in the last 3 years. He receives authorship royalties from Oxford Press and ArtMed. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the last 3 years: Eli-Lilly, Janssen-Cilag, Novartis, and Shire. He also received travel awards from Novartis and Shire to attend the 2015 WFADHD and the 2016 AACAP meetings.